These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 21713326)

  • 21. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate.
    Bonello L; Tantry US; Marcucci R; Blindt R; Angiolillo DJ; Becker R; Bhatt DL; Cattaneo M; Collet JP; Cuisset T; Gachet C; Montalescot G; Jennings LK; Kereiakes D; Sibbing D; Trenk D; Van Werkum JW; Paganelli F; Price MJ; Waksman R; Gurbel PA;
    J Am Coll Cardiol; 2010 Sep; 56(12):919-33. PubMed ID: 20828644
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The potential role of prasugrel in secondary prevention of ischemic events in patients with acute coronary syndromes.
    Toth PP
    Postgrad Med; 2009 Jan; 121(1):59-72. PubMed ID: 19179814
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antiplatelet therapy prasugrel: a novel platelet ADP P2Y12 receptor antagonist.
    Mousa SA; Jeske WP; Fareed J
    Clin Appl Thromb Hemost; 2010 Apr; 16(2):170-6. PubMed ID: 20299391
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Platelet function monitoring in patients on clopidogrel: What should we learn from GRAVITAS?
    Aradi D; Komócsi A
    Platelets; 2012; 23(3):167-76. PubMed ID: 21958190
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Subacute stent thrombosis owing to complete clopidogrel resistance successfully managed with prasugrel.
    Flaherty MP; Johnston PV; Rade JJ
    J Invasive Cardiol; 2011 Jul; 23(7):300-4. PubMed ID: 21725128
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ticagrelor--a new platelet aggregation inhibitor in patients with acute coronary syndromes. An improvement of other inhibitors?
    Kowalczyk M; Banach M; Mikhailidis DP; Hannam S; Rysz J
    Med Sci Monit; 2009 Dec; 15(12):MS24-30. PubMed ID: 19946242
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Predictive values of post-treatment adenosine diphosphate-induced aggregation and vasodilator-stimulated phosphoprotein index for stent thrombosis after acute coronary syndrome in clopidogrel-treated patients.
    Cuisset T; Frere C; Quilici J; Gaborit B; Castelli C; Poyet R; Bali L; Morange PE; Alessi MC; Bonnet JL
    Am J Cardiol; 2009 Oct; 104(8):1078-82. PubMed ID: 19801028
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis.
    Sibbing D; Braun S; Morath T; Mehilli J; Vogt W; Schömig A; Kastrati A; von Beckerath N
    J Am Coll Cardiol; 2009 Mar; 53(10):849-56. PubMed ID: 19264241
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prasugrel in acute coronary syndrome patients undergoing percutaneous coronary intervention.
    Capranzano P; Ferreiro JL; Angiolillo DJ
    Expert Rev Cardiovasc Ther; 2009 Apr; 7(4):361-9. PubMed ID: 19379060
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antiplatelet intervention in acute coronary syndrome.
    Arora RR; Rai F
    Am J Ther; 2009; 16(5):e29-40. PubMed ID: 19092648
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High post-treatment platelet reactivity is associated with a high incidence of myonecrosis after stenting for non-ST elevation acute coronary syndromes.
    Cuisset T; Frere C; Quilici J; Morange PE; Nait-Saidi L; Mielot C; Bali L; Lambert M; Alessi MC; Bonnet JL
    Thromb Haemost; 2007 Feb; 97(2):282-7. PubMed ID: 17264958
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Peri-operative platelet function testing: the potential for reducing ischaemic and bleeding risks.
    Gurbel PA; Mahla E; Tantry US
    Thromb Haemost; 2011 Aug; 106(2):248-52. PubMed ID: 21505715
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Functional impact of high clopidogrel maintenance dosing in patients undergoing elective percutaneous coronary interventions. Results of a randomized study.
    Angiolillo DJ; Bernardo E; Palazuelos J; Desai B; Weisberg I; Alfonso F; Guzman LA; Hernández-Antolin R; Zenni MZ; Macaya C; Fernandez-Ortiz A; Bass TA
    Thromb Haemost; 2008 Jan; 99(1):161-8. PubMed ID: 18217149
    [TBL] [Abstract][Full Text] [Related]  

  • 34. P2Y12 receptor gene polymorphism and antiplatelet effect of clopidogrel in patients with coronary artery disease after coronary stenting.
    Zoheir N; Abd Elhamid S; Abulata N; El Sobky M; Khafagy D; Mostafa A
    Blood Coagul Fibrinolysis; 2013 Jul; 24(5):525-31. PubMed ID: 23751603
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of platelet reactivity on clinical outcomes after percutaneous coronary intervention. A collaborative meta-analysis of individual participant data.
    Brar SS; ten Berg J; Marcucci R; Price MJ; Valgimigli M; Kim HS; Patti G; Breet NJ; DiSciascio G; Cuisset T; Dangas G
    J Am Coll Cardiol; 2011 Nov; 58(19):1945-54. PubMed ID: 22032704
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cardiovascular mortality in chronic kidney disease patients undergoing percutaneous coronary intervention is mainly related to impaired P2Y12 inhibition by clopidogrel.
    Morel O; El Ghannudi S; Jesel L; Radulescu B; Meyer N; Wiesel ML; Caillard S; Campia U; Moulin B; Gachet C; Ohlmann P
    J Am Coll Cardiol; 2011 Jan; 57(4):399-408. PubMed ID: 21251579
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO (PLATelet inhibition and patient Outcomes) PLATELET substudy.
    Storey RF; Angiolillo DJ; Patil SB; Desai B; Ecob R; Husted S; Emanuelsson H; Cannon CP; Becker RC; Wallentin L
    J Am Coll Cardiol; 2010 Oct; 56(18):1456-62. PubMed ID: 20832963
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical outcomes of high on-treatment platelet reactivity in Koreans receiving elective percutaneous coronary intervention (from results of the CROSS VERIFY study).
    Park KW; Jeon KH; Kang SH; Oh IY; Cho HJ; Lee HY; Kang HJ; Park SK; Koo BK; Oh BH; Park YB; Kim HS
    Am J Cardiol; 2011 Dec; 108(11):1556-63. PubMed ID: 21880289
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Platelet P2Y₁₂ receptor inhibition: an update on clinical drug development.
    Vivas D; Angiolillo DJ
    Am J Cardiovasc Drugs; 2010; 10(4):217-26. PubMed ID: 20653328
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ticagrelor: a novel reversible oral antiplatelet agent.
    Nawarskas JJ; Clark SM
    Cardiol Rev; 2011; 19(2):95-100. PubMed ID: 21285670
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.